SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Vaag Allan A.)
 

Sökning: WFRF:(Vaag Allan A.) > Effect of adjunct m...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003804naa a2200481 4500
001oai:lup.lub.lu.se:98b7d895-d603-4b53-b8f9-28362012f9de
003SwePub
008160401s2009 | |||||||||||000 ||eng|
0247 a https://lup.lub.lu.se/record/14923812 URI
0247 a https://doi.org/10.1111/j.1463-1326.2009.01079.x2 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Lund, S. S.4 aut
2451 0a Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes
264 1b Wiley,c 2009
520 a Background In addition to its glucose-lowering effect, metformin treatment has been suggested to improve lipidaemia in patients with type 2 diabetes. In contrast, in patients with type 1 diabetes (T1DM), information about the effect of metformin treatment on lipidaemia is limited. In this study, we report the effect of a 1-year treatment with metformin vs. placebo on plasma lipids in T1DM patients and persistent poor glycaemic control. Methods One hundred T1DM patients with haemoglobinA(1c) (HbA(1c)) >= 8.5% during the year before enrolment entered a 1-month run-in period on placebo treatment. Thereafter, patients were randomized (baseline) to treatment with either metformin (1000 mg twice daily) or placebo for 12 months (double masked). Patients continued ongoing insulin therapy and their usual outpatient clinical care. Outcomes were assessed at baseline and after 1 year. Results After 1 year, in those patients who did not start or stop statin therapy during the trial, metformin treatment significantly reduced total and LDL cholesterol by approximately 0.3 mmol/l compared with placebo (p = 0.021 and p = 0.018 respectively). Adjustment for statin use or known cardiovascular disease did not change conclusions. In statin users (metformin: n = 22, placebo: n = 13), metformin significantly lowered levels of LDL and non-HDL cholesterol by approximately 0.5 mmol/l compared with placebo (adjusted for changes in statin dose or agent: p = 0.048 and p = 0.033 respectively). HbA(1c) (previously reported) was not significant different between treatments. Conclusion In patients with poorly controlled T1DM, at similar glycaemic levels, adjunct metformin therapy during 1 year significantly lowered levels of proatherogenic cholesterolaemia independent of statin therapy.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Endokrinologi och diabetes0 (SwePub)302052 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Endocrinology and Diabetes0 (SwePub)302052 hsv//eng
653 a cholesterol
653 a LDL
653 a statins
653 a Type 1 diabetes mellitus
653 a metformin
653 a lipids
7001 a Tarnow, L.4 aut
7001 a Astrup, A. S.4 aut
7001 a Hovind, P.4 aut
7001 a Jacobsen, P. K.4 aut
7001 a Alibegovic, A. C.4 aut
7001 a Parving, I.4 aut
7001 a Pietraszek, L.4 aut
7001 a Frandsen, M.4 aut
7001 a Rossing, P.4 aut
7001 a Parving, H. -H.4 aut
7001 a Vaag, Allanu Lund University,Lunds universitet,Genomik, diabetes och endokrinologi,Forskargrupper vid Lunds universitet,Genomics, Diabetes and Endocrinology,Lund University Research Groups4 aut0 (Swepub:lu)med-ava
7102 a Genomik, diabetes och endokrinologib Forskargrupper vid Lunds universitet4 org
7730 t Diabetes, Obesity and Metabolismd : Wileyg 11:10, s. 966-977q 11:10<966-977x 1462-8902x 1463-1326
8564 u http://dx.doi.org/10.1111/j.1463-1326.2009.01079.xy FULLTEXT
8564 8u https://lup.lub.lu.se/record/1492381
8564 8u https://doi.org/10.1111/j.1463-1326.2009.01079.x

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy